louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01873664: Functional Magnetic Resonance Imaging Study of Jaw-tapping Movement on Memory Function
Official title: Brain Activity During Jaw Tapping Movement in Healthy Subjects and Mild Cognitive Impairment Patients Using Functional Magnetic Resonance Imaging
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Memory Disturbances
Keywords: fMRI
Jaw tapping
Memory disorder
Mild cognitive impairment
MCI
Working memory
Lead sponsor: Kyunghee University Medical Center
Sponsor class: OTHER
Collaborators: name: Kyung Hee University Hospital at Gangdong
First posted: 2013-06-10
Enrollment: 30
Sex: FEMALE
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to examine the possibility of using jaw-tapping training as a self-exercise for developing memory and preventing dementia in elderly subjects with memory disturbances using functional magnetic resonance imaging (fMRI).

Detailed description: Right-handed female volunteers over the age of 50 years with subjective memory complaints are included in the study. Volunteers with dentures, psychoactive medication, history of stroke, or other neurologic disorders are excluded.

The protocol was approved by the Institutional Review Board of university-based hospital.

After administering the Seoul Neuropsychological Screening Battery (SNSB), Mini-Mental State Examination (MMSE) scores above 24 and Clinical Dementia Rating Scale (CDR) scores of 0 are considered subjective memory complaints (SMC), and MMSE scores above 23 and CDR scores of 0.5 are considered MCI.

All subjects undergo two MRI scans. After the first MRI, the subjects are trained to tap their jaws vertically at 1.6 Hz at home twice a day for 30 seconds every day during four weeks.

Eligibility criteria: Inclusion Criteria:

* Right-handed female volunteers over the age of 50 years with subjective memory complaints

Exclusion Criteria:

* Volunteers with dentures, psychoactive medication, history of stroke, or other neurologic disorders

Primary outcomes:
measure: Brain activity of n-back task
timeFrame: up to 4 weeks
Secondary outcomes:
measure: Brain activity of jaw-tapping task
timeFrame: baseline and 4 weeks
Other outcomes:
measure: Performance scores of the n-back task
timeFrame: baseline and 4 weeks
Locations:
city: Seoul
country: Korea, Republic of
facility: Kyung Hee University Hospital at Gangdong
Study officials:
affiliation: Professor, Kyung Hee University
name: Jung-Mi Park, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01627964: Motion Analysis and Assessment of Cardiac Function for Cardiac Images
Official title: Motion Analysis and Assessment of Cardiac Function for Cardiac Images
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Heart; Functional Disturbance
Keywords: Heart Wall Motion Function
Lead sponsor: Far Eastern Memorial Hospital
Sponsor class: OTHER
First posted: 2012-06-26
Enrollment: 20
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: randomly selected patients

Brief summary: The study develops software for motion analysis and assessment of cardiac function for cardiac images. Cardiac catheterization ventriculography of several randomly selected patients were taken from our hospital's PACS system. The investigators remove the patient information on the images, and use the image for motion analysis and assessment.

Detailed description: The study develops software for motion analysis and assessment of cardiac function for cardiac images. Twenty patients who have both cardiac catheterization ventriculography and cardiac echo studies will be randomly selected. Cardiac catheterization ventriculography of the selected patients were taken from our hospital's PACS system. The investigators remove the patient information on the images, and use the image for motion analysis and assessment. The results will be compared and correlated with their cardiac echo, which could validate the clinical usefulness of the software.

Eligibility criteria: Inclusion Criteria:

* patients who already have cardiac catheterization ventriculography and cardiac echo studies.

Exclusion Criteria:

* patients who do not have either cardiac catheterization ventriculography or cardiac echo studies.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: New Taipei
country: Taiwan
facility: Far Eastern Memorial Hospital
Study officials:
affiliation: Far Eastern Memorial Hospital
name: Yu-Chien Shiau, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bravo A, Medina R. An unsupervised clustering framework for automatic segmentation of left ventricle cavity in human heart angiograms. Comput Med Imaging Graph. 2008 Jul;32(5):396-408. doi: 10.1016/j.compmedimag.2008.03.003.
citation: White RD, Setser RM. Integrated approach to evaluating coronary artery disease and ischemic heart disease. Am J Cardiol. 2002 Nov 21;90(10C):49L-55L. doi: 10.1016/s0002-9149(02)02964-8.
citation: Oost E, Koning G, Sonka M, Oemrawsingh PV, Reiber JH, Lelieveldt BP. Automated contour detection in X-ray left ventricular angiograms using multiview active appearance models and dynamic programming. IEEE Trans Med Imaging. 2006 Sep;25(9):1158-71. doi: 10.1109/tmi.2006.877094.
citation: Suzuki K, Horiba I, Sugie N, Nanki M. Extraction of left ventricular contours from left ventriculograms by means of a neural edge detector. IEEE Trans Med Imaging. 2004 Mar;23(3):330-9. doi: 10.1109/TMI.2004.824238.
Clinical trial NCT03973164: The Value of Pelvic Magnetic Resonance Imaging in Detecting Bone Marrow Infiltration of Lymphoma
Official title: Bone Marrow Cytology, Pathology and 18F-FDG PET/CT and Pelvic MRI in the Diagnosis of Lymphoma Bone Marrow Invasion
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Lymphoma
Lead sponsor: Guangxi Medical University
Sponsor class: OTHER
First posted: 2019-06-04
Enrollment: 142
Sex: ALL
Minimum age (years): 8
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study population was an Asian race with lymphoma.

Brief summary: The diagnosis of lymphoma bone marrow infiltration is very important for the staging and treatment mode of lymphoma. Traditional bone marrow cytology and pathology examinations are only performed locally, and missed diagnosis is possible. The study explore the value of multi-parameter pelvic magnetic resonance in detecting bone marrow infiltration with newly diagnosed lymphoma patients . This study also explore the consistency of pelvic magnetic resonance and PET/CT for detection of lymphoma bone marrow infiltration.


Eligibility criteria: Inclusion Criteria:

* Lymphoma subtypes were diagnosed on the basis of tissue samples obtained by biopsy or surgery according to the criteria outlined in the current World Health Organization (WHO) classification of hematologic and lymphoid malignancies, by are reference pathologist.
* Patients who gave written informed consent were referred for MRI.
* Stable physical medical conditions (patients conscious and comfortable, scheduled for an elective diagnostic imaging).

Exclusion Criteria:

• Pregnancy, general contraindications to MRI.

Primary outcomes:
measure: Agreement Between MRI and Bone marrow cytology, pathology and follow-up at Diagnosis
timeFrame: Within 30 days prior to start of chemotherapy
Secondary outcomes:
measure: Agreement Between MRI and 18F-FDG PET/CT at Diagnosis
timeFrame: Within 30 days prior to start of chemotherapy
Other outcomes:
Locations:
city: Nanning
country: China
facility: Affiliated Tumor Hospital，Guangxi Medical University
Study officials:
References:
citation: Barrington SF, Mikhaeel NG, Kostakoglu L, Meignan M, Hutchings M, Mueller SP, Schwartz LH, Zucca E, Fisher RI, Trotman J, Hoekstra OS, Hicks RJ, O'Doherty MJ, Hustinx R, Biggi A, Cheson BD. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014 Sep 20;32(27):3048-58. doi: 10.1200/JCO.2013.53.5229.
Clinical trial NCT03928964: MEtatastic Renal Carcinoma LINes
Official title: Pronostic Assessment of Mortality Among Locally Advanced or Metastatic Renal Cell Carcinoma Patients After First Line Treatment : Multicenter Prospective Cohort Study With Historic Medical Data
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Renal Cell Carcinoma
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
First posted: 2019-04-26
Enrollment: 440
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with locally advanced or metastatic renal cell carcinoma, whose first-line treatment included at least one anti-angiogenic agent (tyrosine kinase inhibitor or monoclonal antibodies) and / or an mTOR inhibitor

Brief summary: The hypothesis of this study are as follows:

* Prognostic evaluation of patients based on an integrative model provides better assessment of overall survival, and thus improves setting of care goals.
* In a routine care population, antitumour drugs may have a significant impact on overall survival through their targeted antitumor effect, but also through their toxicity profile and their impact on comorbidities.
* The optimization of patient support (supportive care, drug tolerance monitoring) can have an impact on the prognosis.


Eligibility criteria: Inclusion criteria:

1. Patients with locally advanced or metastatic renal cell carcinoma
2. Whose first-line treatment included at least one anti-angiogenic agent (tyrosine kinase inhibitor or monoclonal antibodies) and / or an mTOR inhibitor;
3. Whatever was the overall ECOG-PS score (Eastern Cooperative Oncology Group Performance Status) at treatment initiation time
4. With first-line treatment carried out between 2007 and June 2016.

Exclusion criteria:

1. Patient previously treated with only one cytokine (Interferon α2a, high-dose interleukin-2)
2. Refusal of processing of personal data

Primary outcomes:
measure: Overall survival after the first line of treatment
timeFrame: year 11
Secondary outcomes:
Other outcomes:
Locations:
city: Besançon
country: France
facility: CHU de Besançon
city: Créteil
country: France
facility: Hôpital Henri Mondor
city: Montbéliard
country: France
facility: Hôpital Nord Franche-Comté Montbéliard
city: Paris
country: France
facility: Hôpital Cochin
city: Paris
country: France
facility: Hôpital Européen Georges Pompidou
city: Paris
country: France
facility: Hôpital Saint-Louis
city: Paris
country: France
facility: Institut Mutualiste Montsouris
city: Saint-Mandé
country: France
facility: Hôpital d'Instruction des Armées de Bégin
Study officials:
affiliation: Henri Mondor University Hospital
name: Benoit Rousseau, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00763464: Coronary Artery Disease (CAD) in Postmenopausal Women
Official title: Coronary Artery Disease in Postmenopausal Women. Comparison of Myocardial Szintigraphy With Sress-Echocardiography and Stress-MRI.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Postmenopausal Women
Stable Angina Pectoris
Keywords: Coronary Artery Disease
ischemia diagnostic
Lead sponsor: RWTH Aachen University
Sponsor class: OTHER
First posted: 2008-10-01
Enrollment: 100
Sex: FEMALE
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Aim of this study is the determination of a valid procedure for ischemia diagnositc in postmenopausal women.

Detailed description: In order to investigate which ischemia diagnostic presents which sensitivity and specificity for postmenopausal women, 100 consecutive patients presenting to our abmulance with stable angina pectoris and indication for myocardial szintigraphy will be enrolled in this study. An addidional stress-echocardiography and stress-MRI will be performed in this patients before they will reiceve their again routine coronay angiography.

The different methods for ischemia diagnostic will be compared in order to determine the most valid method for this specific population.

Eligibility criteria: Inclusion Criteria:

* Postmenopausal women presenting to the hospital with stable Angina pectoris complaints and an indication for myocardial szintigraphy

Exclusion Criteria:

* CABG
* Pacemaker or other metal implants
* Chronic bronchitis
* Asthma bronchiale
* Arterial Hypotension

Primary outcomes:
measure: comparision of different ischemia diagnostic methods
timeFrame: before routine coronary angiography
Secondary outcomes:
Other outcomes:
Locations:
city: Aachen
country: Germany
facility: Department of Cardiology, RWTH Aachen University Hospital
Study officials:
affiliation: Medical Faculty of the RWTH Aachen University
name: Michael Becker, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04593264: Quantifying the Benefits of Supervised vs. Unsupervised Pre-habilitation for Patients With Acute ACL Tears
Official title: Quantifying the Benefits of Supervised vs. Unsupervised Pre-habilitation for Patients With Acute ACL Tears
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anterior Cruciate Ligament Rupture
Anterior Cruciate Ligament Tear
Anterior Cruciate Ligament Injuries
Lead sponsor: WellSpan Health
Sponsor class: OTHER
First posted: 2020-10-19
Enrollment: 128
Sex: ALL
Minimum age (years): 13
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Although the success of physical therapy following surgery has been well-documented and validated in patients undergoing Anterior Cruciate Ligament Reconstruction (ACLR) procedures, more recent studies have demonstrated that patient outcomes are the most favorable when surgery is delayed approximately 4 weeks until after the patient has completed a preoperative physical therapy program, or "pre-habilitation." The ultimate goal of pre-habilitation is to regain full range of motion in the knee and reach approximately 80% of pre-injury quadricep strength. However, extra physical therapy can stress both time and resources. Thus, we propose a home-based, self-guided pre-habilitation program. We hypothesize that patients participating in self-guided pre-habilitation will experience the same benefits as patients in a traditional office-based physical therapy program.


Eligibility criteria: Inclusion Criteria:

* Skeletal maturity
* Acute ACL rupture occurring no longer than 4 weeks prior to presentation
* Ability to participate in a pre-habilitation program
* Nature of the injury allows adequate time for pre-habilitation
* Ability to speak, read, and understand English
* Willing and able to provide informed consent

Exclusion Criteria:

* Any injuries requiring immediate surgical intervention
* Ipsilateral meniscus tear that preventing participation in a pre-habilitation program
* Ipsilateral MCL tears grade III
* Ipsilateral PCL tears (any grade)
* Concomitant LCL injuries
* Concomitant posterolateral corner injuries
* Inflammatory arthritis
* Prior ACL rupture/reconstruction
* Anyone unable to participate in a stretching/strengthening program

Primary outcomes:
measure: Number of Participants Ready for ACL repair surgery
timeFrame: Approximately 4 weeks following initiation of a pre-habilitation program
Secondary outcomes:
measure: Knee Range of Motion
timeFrame: Approximately 4 weeks following initiation of a pre-habilitation program
measure: Thigh circumference
timeFrame: Approximately 4 weeks following initiation of a pre-habilitation program
Other outcomes:
Locations:
city: York
country: United States
facility: WellSpan Health
state: Pennsylvania
Study officials:
References:
Clinical trial NCT05596864: Transabdominal Gastric Contrast Ultrasound
Official title: Application Value of Transabdominal Gastric Contrast Ultrasound in the Diagnosis and Staging Evaluation of Gastric Cancer
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Transabdominal Gastric Contrast Ultrasound
Lead sponsor: The First Hospital of Jilin University
Sponsor class: OTHER
First posted: 2022-10-27
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with gastric cancer who are ready for surgery

Brief summary: In this study, the clinical data of patients diagnosed with gastric cancer who were ready for surgery were examined by contrast-enhanced ultrasonography and gastric-enhanced CT before surgery. Based on the results of postoperative pathological examinations, the diagnostic accuracy of gastric filling contrast-enhanced ultrasonography and gastric contrast-enhanced CT in different stages of gastric cancer was compared and analyzed. Provide better guidance for follow-up clinical practice.


Eligibility criteria: Inclusion Criteria:

1. Age: 18\~80 years old, male or female;
2. Diagnosed with gastric cancer by histology or cytology;
3. No distant multiple metastasis;
4. ECOG score 0-2;
5. Heart, lung, liver and kidney function can tolerate surgery;
6. Patients and their families can understand and be willing to participate in this clinical study, and sign the informed consent.

Exclusion Criteria:

1. Previous history of malignant tumor or recent diagnosis combined with other malignant tumors;
2. Patients with gastrointestinal perforation, gastrointestinal bleeding, etc. requiring emergency surgery;
3. Patients with previous gastroduodenal surgery;
4. Preoperative neoadjuvant therapy;
5. Patients and their families refuse surgical treatment;
6. ASA grade ≥ IV and/or ECOG performance status score \> 2;
7. Patients with severe liver and kidney function, cardiopulmonary function, coagulation dysfunction or combined with serious underlying diseases who cannot tolerate surgery;
8. Have a history of serious mental illness;
9. Pregnant or lactating women;
10. Patients with other clinical and laboratory conditions considered by the researchers should not participate in this trial.

Primary outcomes:
measure: Sensitivity, specificity and accuracy of gastric contrast ultrasound in judging gastric cancer staging.
timeFrame: one month after surgery
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: The First Hospital of Jilin University
name: Wei Li, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00777764: The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)
Official title: The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Healthy
Asthma
Keywords: Xolair
Asthma
Skin Tests
Lead sponsor: Genentech, Inc.
Sponsor class: INDUSTRY
First posted: 2008-10-22
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study enrolled 30 healthy volunteers and 30 patients with atopic asthma, for a total of 60 subjects. The study examined the tolerability of omalizumab and omalizumab excipients in two successive cohorts of subjects, healthy volunteers and patients with allergic asthma without prior exposure to omalizumab, according to a skin test protocol, consisting of a prick skin test and/or intradermal test.


Eligibility criteria: Inclusion Criteria:

* (Applicable to healthy subjects only) Healthy subjects not taking any regular prescription medication, without history of allergy, and considered healthy by the physician
* (Applicable to asthma patients only) Patients with atopic asthma diagnosed by a physician with asthma and history of positive skin test(s)
* Physical examination findings within normal limits
* Body mass index (BMI) between 18 and 30, inclusive

Exclusion Criteria:

* Pregnancy and lactation
* Current or previous treatment with a biologic agent (e.g., monoclonal antibody)
* Concurrent disease or condition that would interfere, or for which the treatment might interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to individuals in this study
* History or symptoms of significant psychiatric disease, including but not limited to, depression, schizophrenia, etc.
* History of drug abuse
* Participation in an investigational drug or device trial within the last 30 days prior to screening

Primary outcomes:
measure: Number of Participants by of Adverse Events Following a Skin Test Procedure
timeFrame: Up to 7 days following skin testing
measure: Number of Participants Who Experienced a Positive Skin Reaction (Skin Prick Test)
timeFrame: on the day of skin test
measure: Number of Participants Who Experienced a Positive Skin Reaction (Intradermal Test in Healthy Volunteers)
timeFrame: on the day of skin test
measure: Number of Participants Who Experienced a Positive Skin Reaction (Intradermal Test in Patients With Allergic Asthma)
timeFrame: on the day of skin test
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Genentech, Inc.
name: Dennis Wong, M.D.
role: STUDY_DIRECTOR
References: